Comparative study on efficacy and safety between premixed insulin aspart 30 regimens of twice daily versus injection,triple-daily regimen in treatment of serious type 2 diabetes

被引：1
|
作者：
秦健 [1 ]
机构：
[1] Dept Endocrinol,Qingdao 8th People’s Hosp
来源：
China Medical Abstracts (Internal Medicine) | 2012年 / 29卷 / 04期
关键词：
Comparative study on efficacy and safety between premixed insulin aspart 30 regimens of twice daily versus injection; triple-daily regimen in treatment of serious type 2 diabetes;
D O I：
暂无
中图分类号：
R587.1 [糖尿病];
学科分类号：
1002 ; 100201 ;
摘要：
Objective To compare the efficacy and safety between twice- and triple-daily subcutaneous injection of premixed insulin aspart 30 ( BIAsp30) in serious T2DM patients with failure of oral anti-diabetic drugs(OADs) . Methods Fifty-six patients with inadequate control of hyper-glycemia by OADs were randomized into two groups
引用
收藏
页码：206 / 206
页数：1
相关论文
共 50 条
  • [1] Comparison of a twice daily injection of insulin aspart 50 with insulin aspart 30 in patients with poorly controlled type 2 diabetes
    Shi, Chunhong
    Sun, Luyan
    Bai, Ran
    Wang, Hao
    Liu, Dan
    Du, Jianling
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2019, 35 (06) : 1091 - 1096
  • [2] Exenatide Twice Daily Plus Glargine Versus Aspart 70/30 Twice Daily in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Premixed Human Insulin and Metformin
    Chen, Xi
    Xu, Yongping
    Zhang, Jianhua
    Shao, Shiyin
    Duan, Yanran
    Liu, Peiwen
    Shen, Liya
    Zhang, Jing
    Zeng, Jiaoe
    Lin, Mei
    Zhao, Shi
    Ma, Jianhua
    Zhao, Tao
    Hu, Juping
    Liao, Yong
    Chen, Xiaowen
    Hu, Shufang
    Xue, Yaoming
    Zeng, Zhaoyang
    He, Wentao
    Liu, Zhelong
    Li, Wenjun
    Liu, Liegang
    Yin, Ping
    Yu, Xuefeng
    [J]. ENDOCRINE PRACTICE, 2021, 27 (08) : 790 - 797
  • [3] A Thrice Daily Regimen with Biphasic Insulin Aspart 50 Is More Effective and as Safe as Twice Daily Biphasic Insulin Aspart 30 in Chinese Subjects with Type 2 Diabetes
    Gao, Yan
    [J]. DIABETES, 2010, 59 : A153 - A153
  • [4] Efficacy and safety of twice daily vs. thrice daily injections of biphasic insulin aspart 30 in insulin naive patients with type 2 diabetes inadequately controlled with OADs
    Yang, Wenying
    Ji, Qiuhe
    Zhu, Dalong
    Yang, Jinkui
    Chen, Lulu
    Liu, Zhimin
    Yu, Demin
    Yan, Li
    [J]. DIABETES, 2007, 56 : A546 - A546
  • [5] Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in Type 1 and Type 2 diabetic patients
    Boehm, BO
    Home, PD
    Behrendt, C
    Kampt, NM
    Lindholm, A
    [J]. DIABETIC MEDICINE, 2002, 19 (05) : 393 - 399
  • [6] Efficacy and safety of three-times-daily versus twice-daily biphasic insulin aspart 30 in patients with type 2 diabetes mellitus inadequately controlled with basal insulin combined with oral antidiabetic drugs
    Yang, Wenying
    Ersoy, Canan
    Wang, Guixia
    Ye, Shandong
    Liu, Jun
    Miao, Heng
    Asirvatham, Arthur
    Werther, Shanti
    Kadu, Priti
    Chow, Francis
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2019, 150 : 158 - 166
  • [7] Thrice-daily biphasic insulin aspart 30 is more effective and as safe as a twice-daily regimen in subjects with type 2 diabetes inadequately controlled with OADs
    Yang, W.
    Ji, Q.
    Zhu, D.
    Yang, J.
    Chen, L.
    Liu, Z.
    Yu, D.
    Yan, L.
    [J]. DIABETOLOGIA, 2007, 50 : S409 - S409
  • [8] Efficacy and Safety of Twice Daily Remogliflozin Etabonate for the Treatment of Type 2 Diabetes
    Sykes, Andy
    Wilkison, William O.
    Kler, Lata
    Lorimer, Jamie
    Dorey, David
    Dobbins, Robert L.
    O'Connor-Semmes, Robin
    [J]. DIABETES, 2014, 63 : A287 - A287
  • [9] Insulin degludec/insulin aspart vs biphasic insulin aspart 30 twice daily in Japanese patients with type 2 diabetes: A randomized controlled trial
    Onishi, Yukiko
    Yamada, Kenichi
    Zacho, Jeppe
    Ekelund, Jan
    Iwamoto, Yasuhiko
    [J]. JOURNAL OF DIABETES INVESTIGATION, 2017, 8 (02) : 210 - 217
  • [10] Starting insulin therapy in type 2 diabetes: Twice-daily biphasic insulin aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride
    Kann, P. H.
    Wascher, T.
    Zackova, V.
    Moeller, J.
    Medding, J.
    Szocs, A.
    Mokan, M.
    Mrevlje, F.
    Regulski, M.
    [J]. EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2006, 114 (09) : 527 - 532
12345